Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Related Keywords

California , United States , San Francisco , , Myeloma Program , University Of California , Helen Diller Family Comprehensive Cancer Center , Findings From , Refractory Multiple , Multiple Myeloma Program , Diller Family Comprehensive Cancer Center , Ash Annual Meeting And Exposition , Onclive Tv , Multiple Myeloma ,